Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100

PARAMUS, N.J., Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Polaryx Therapeutics, Inc. is a biotech company developing patient-friendly oral small molecule therapeutics for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and other form... Biopharmaceuticals, Neurology, FDA Polaryx Therapeutics, Neuronal Ceroid Lipofuscinoses
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news